Colon cancer hepatic resection, Colon cancer hepatic resection, Medical Ultrasonography, June
Sarcopenia represents a decrease in the skeletal muscle mass colon cancer hepatic resection function and is usually associated with colon cancer hepatic resection aging process.
The prevalence of sarcopenia in patients with gastric cancer is reported to be as high as Although many studies support the negative impact of sarcopenia in patients with gastric cancer, contradictory results are also present in the literature. The objective of this study is to investigate if sarcopenia is correlated with increased morbidity and mortality, colon cancer hepatic resection patients with gastric adenocarcinoma.
Colon cancer hepatic resection We studied retrospectively all patients having radical resection for colon cancer hepatic resection adenocarcinoma managed in the Emergency Hospital of Bucharest between December and May ImageJ software was used to measure the patients' body composition.
We identified the L3 landmark and extracted that corresponding single cross-sectional image contained within a CT study.
Results: We reviewed colon cancer hepatic resection patients who had gastrectomy for cancer, but 11 Computed Tomography images were not available colon cancer hepatic resection analysis. Therefore, the study group consisted of 78 patients of which 50 were The average age of patients diagnosed with gastric cancer was The primary tumor location was the middle third of the stomach in 45 patients There were 72 The average sarcopenia value for both males and females is The greatest number of patients had a skeletal muscle index between The second greatest is colon cancer hepatic resection The muscular skeletal index correlated with the age of the patients.
The overall complications rate and the surgical site infection rate correlated with the sarcopenia. Conclusions: Sarcopenia is highly prevalent in patients having surgery for gastric cancer in Romania and correlates with increased postoperative morbidity.
Especially with the increased trend for neoadjuvant therapy, the multidisciplinary team should evaluate and address sarcopenia through the perioperative period.